Trial Profile
A Double-Blind, Double Dummy, Randomized, Placebo-Controlled, Alternating Panel, Single Oral Rising Dose Study to Assess the Pharmacokinetics and Pharmacodynamics of MK1809 in Healthy Young Volunteers
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 11 May 2022
Price :
$35
*
At a glance
- Drugs MK 1809 (Primary) ; Losartan
- Indications Hypertension
- Focus Adverse reactions; Pharmacokinetics
- Acronyms COMPLETED
- Sponsors Merck Sharp & Dohme Corp.
- 29 Dec 2009 New trial record